Online inquiry

IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4646MR)

This product GTTS-WQ4646MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets FGFR1 gene. The antibody can be applied in Non-alcoholic steatohepatitis (NASH) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001174063.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2260
UniProt ID P11362
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4646MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14602MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SAR-650984
GTTS-WQ2537MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 477
GTTS-WQ6279MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CS-1001
GTTS-WQ2557MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 479
GTTS-WQ3164MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AR-101
GTTS-WQ8351MR IVTScrip™ mRNA-Anti-MUC1, hPAM4(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA hPAM4
GTTS-WQ13256MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-05335810
GTTS-WQ14994MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW